RIG-I and TLR-7/8 agonists as combination adjuvant shapes unique antibody and cellular vaccine responses to seasonal influenza vaccine.
Author
Jangra, SoniaLaghlali, Gabriel
Choi, Angela
Rathnasinghe, Raveen
Chen, Yong
Yildiz, Soner
Coughlan, Lynda
García-Sastre, Adolfo
De Geest, Bruno G
Schotsaert, Michael
Date
2022-11-08Journal
Frontiers in immunologyType
Article
Metadata
Show full item recordRights/Terms
Copyright © 2022 Jangra, Laghlali, Choi, Rathnasinghe, Chen, Yildiz, Coughlan, García-Sastre, De Geest and Schotsaert.Identifier to cite or link to this item
http://hdl.handle.net/10713/20267ae974a485f413a2113503eed53cd6c53
10.3389/fimmu.2022.974016
Scopus Count
Collections
Related articles
- Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Modified Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine.
- Authors: Jangra S, De Vrieze J, Choi A, Rathnasinghe R, Laghlali G, Uvyn A, Van Herck S, Nuhn L, Deswarte K, Zhong Z, Sanders N, Lienenklaus S, David S, Strohmeier S, Amanat F, Krammer F, Hammad H, Lambrecht BN, Coughlan L, García-Sastre A, De Geest BG, Schotsaert M
- Issue date: 2020 Oct 23
- A Novel Synthetic Dual Agonistic Liposomal TLR4/7 Adjuvant Promotes Broad Immune Responses in an Influenza Vaccine With Minimal Reactogenicity.
- Authors: Sato-Kaneko F, Yao S, Lao FS, Shpigelman J, Messer K, Pu M, Shukla NM, Cottam HB, Chan M, Chu PJ, Burkhart D, Schoener R, Matsutani T, Carson DA, Corr M, Hayashi T
- Issue date: 2020
- Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
- Authors: Goff PH, Hayashi T, Martínez-Gil L, Corr M, Crain B, Yao S, Cottam HB, Chan M, Ramos I, Eggink D, Heshmati M, Krammer F, Messer K, Pu M, Fernandez-Sesma A, Palese P, Carson DA
- Issue date: 2015 Mar
- Fc functional antibody responses to adjuvanted versus unadjuvanted seasonal influenza vaccination in community-dwelling older adults.
- Authors: Vanderven HA, Barr I, Reynaldi A, Wheatley AK, Wines BD, Davenport MP, Hogarth PM, Kent SJ
- Issue date: 2020 Feb 28
- Adjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.
- Authors: Fotouhi F, Shaffifar M, Farahmand B, Shirian S, Saeidi M, Tabarraei A, Gorji A, Ghaemi A
- Issue date: 2017 May